UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 10, 2004 (December 9, 2004)
Introgen Therapeutics, Inc.
Delaware
|
0-21291 | 74-2704230 | ||
(State or other jurisdiction
|
(Commission | (IRS Employer | ||
of incorporation)
|
File Number) | Identification No.) | ||
301 Congress Avenue, Suite 1850, Austin, Texas
|
78701 | |||
(Address of principal executive offices)
|
(Zip Code) | |||
Registrant’s telephone number, including area code: (512) 708-9310
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| Item 8.01. Other Events. | ||||||||
| Item 9.01. Financial Statements and Exhibits. | ||||||||
| SIGNATURES | ||||||||
| INDEX TO EXHIBITS | ||||||||
| Press Release | ||||||||
Item 8.01. Other Events.
On December 9, 2004, Introgen Therapeutics, Inc. (the “Company”) issued a press release announcing data from a Phase 2 clinical trial of ADVEXIN therapy, the Company’s lead product candidate. The press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein.
Neither the filing of any press release as an exhibit to this Current Report on Form 8-K nor the inclusion in such press release of a reference to the Company’s Internet address shall, under any circumstances, be deemed to incorporate the information available at such Internet address into this Current Report on Form 8-K. The information available at the Company’s Internet address is not part of this Current Report on Form 8-K or any other report filed by the Company with the Securities and Exchange Commission.
Item 9.01. Financial Statements and Exhibits.
(c)
|
Exhibits. | |
99.1
|
Press Release dated December 9, 2004. |
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: December 10, 2004 | INTROGEN THERAPEUTICS, INC. |
|||
| /s/ James W. Albrecht, Jr. | ||||
| James W. Albrecht, Jr. | ||||
| Chief Financial Officer | ||||
-3-